Eli Lilly (LLY) Sees Strong Growth Driven by Mounjaro Momentum and GLP-1 Demand, Barclays Remains Bullish
Key takeaways
- The company reported net income of $20.64 billion for the recently completed fiscal year (FY25).
- That earnings strength was also evident in the April 30, 2026, update.
- Eli Lilly and Company (NYSE:LLY) reported first-quarter 2026 adjusted EPS of $8.55, well above the $6.66 Wall Street consensus tracked by LSEG.
Eli Lilly (LLY) Sees Strong Growth Driven by Mounjaro Momentum and GLP-1 Demand, Barclays Remains Bullish Faheem Tahir Fri, May 22, 2026 at 12:46 AM GMT+7 2 min read LLY NVO Eli Lilly and Company (NYSE:LLY), featuring a net income margin of 34.99% and upside potential of 20.64%, secures a spot on our list of the best extremely profitable stocks to buy according to Wall Street analysts. The company reported net income of $20.64 billion for the recently completed fiscal year (FY25).
That earnings strength was also evident in the April 30, 2026, update.
Eli Lilly and Company (NYSE:LLY) reported first-quarter 2026 adjusted EPS of $8.55, well above the $6.66 Wall Street consensus tracked by LSEG. The company also raised its full-year 2026 adjusted EPS outlook to $35.50-$37.00 from $33.50-$35.00 and lifted revenue guidance to $82-$85 billion from $80-$83 billion.